BriaCell Therapeutics Corp. Warrant
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCTXZ research report →
Price Chart
About the company
BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently undergoing Phase I/IIa clinical trials, where it is being evaluated in combination with the investigational immunotherapy retifanlimab.
- CEO
- William V. Williams
- IPO
- 2025
- Employees
- 31
- HQ
- West Vancouver, BC, CA
Get TickerSpark's AI analysis on BCTXZ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $243.94K
- P/E
- -0.33
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 1.63
- EV/EBITDA
- -0.48
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -170.70%
- ROIC
- -230.00%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $0
- Net Income
- $-34,904,262-31.1%
- EPS
- $-6.97+88.9%
- OCF Growth
- -0.5%
- FCF Growth
- -0.9%
- 52W High
- $0.44
- 52W Low
- $0.06
- 50D MA
- $0.16
- 200D MA
- $0.13
- Beta
- 1.54
- RSI (14)
- 47
- Avg Volume
- 72.66K
No earnings-call transcripts are available for BCTXZ yet.
- Free Float
- 88.4%
- Shares Outstanding
- 1.88M
- Float Shares
- 1.67M
Our BCTXZ coverage
Recent articles, reports, and earnings notes.
No research on BCTXZ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BCTXZ report →